Award
National Eye Institute 5R01EY036033-02
Alloimmune-compatible stem cells for ocular diseases
Recipient
Research Institutes
Award Amount
$492,500.00
Ceiling
$492,500.00
Awarded
January 12, 2026
Identifier
5R01EY036033-02
Award for developing gene-edited immune-compatible stem cells for ocular diseases using CRISPR/Cas9, funded by the National Eye Institute.
Description
The project focuses on developing gene-edited induced pluripotent stem cells (iPSCs) that are immune-compatible for ocular tissue regeneration. It involves gene editing techniques such as CRISPR/Cas9 to modify HLA-I molecules to evade immune rejection. The project aims to produce transgene-free, universally immunocompatible iPSCs for allogeneic stem cell therapy. The project is funded by the National Eye Institute and is part of the PA-20-185 funding opportunity. The project duration is from January 1, 2025, to December 31, 2029. The project involves collaboration with the Schepens Eye Research Institute in Boston.